American Journal of Transplantation

First clinical-grade porcine kidney xenotransplant using a human decedent model.  22:1037-1053. 2022

Prognostic value of silent myocardial infarction in patients with chronic kidney disease after kidney transplantation.  22:1115-1122. 2022

COVID-19 and transplantation—Data censoring 2022

Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic.  22:279-288. 2022

Management of cardiac diseases in liver transplant recipients: Comprehensive review and multidisciplinary practice-based recommendations 2022

Sex and organ-specific risk of major adverse renal or cardiac events in solid organ transplant recipients with COVID-19.  22:245-259. 2022

Telemedicine services for living kidney donation: A US survey of multidisciplinary providers 2022

Bioenergetic maladaptation and release of HMGB1 in calcineurin inhibitor-mediated nephrotoxicity.  21:2964-2977. 2021

Kidney recipients with allograft failure, transition of kidney care (KRAFT): A survey of contemporary practices of transplant providers.  21:3034-3042. 2021

The failing kidney allograft: A review and recommendations for the care and management of a complex group of patients.  21:2937-2949. 2021

COVID-19 in pediatric kidney transplantation: The Improving Renal Outcomes Collaborative.  21:2740-2748. 2021

A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action.  21:1754-1764. 2021

i-IFTA and chronic active T cell–mediated rejection: A tale of 2 (DeKAF) cohorts.  21:1866-1877. 2021

Delayed graft function and acute rejection following HLA-incompatible living donor kidney transplantation.  21:1612-1621. 2021

Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement.  21:475-483. 2021

Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement.  21:460-474. 2021

Clinical trials of pediatric cardiac xenotransplantation.  21:433-434. 2021

Competing risks and the risks of children and adults competing for livers.  21:13-14. 2021

Inflammation in areas of fibrosis: The DeKAF prospective cohort.  20:2509-2521. 2020

Transplant physician and surgeon compensation: A sample framework accounting for nonbillable and value-based work.  20:641-652. 2020

Clarifying the HOPE Act landscape: The challenge of donors with false-positive HIV results.  20:617-619. 2020

Tackling the weight list problem.  20:329-330. 2020

Get on with it!—A novel allocation strategy to reduce kidney discards.  19:2971-2972. 2019

Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups.  19:2795-2804. 2019

WNT pathway signaling is associated with microvascular injury and predicts kidney transplant failure.  19:2833-2845. 2019

Patient-reported outcome measures for life participation in kidney transplantation: A systematic review.  19:2306-2317. 2019

The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population.  19:2262-2273. 2019

Variation in use of procurement biopsies and its implications for discard of deceased donor kidneys recovered for transplantation.  19:2241-2251. 2019

Time for reform in transplant program–specific reporting: AST/ASTS transplant metrics taskforce.  19:1888-1895. 2019

Optimal timing of hepatitis C treatment among HIV/HCV coinfected ESRD patients: Pre- vs posttransplant.  19:1806-1819. 2019

Long-term follow-up of the DeKAF cross-sectional cohort study.  19:1432-1443. 2019

Repeat kidney transplant recipients with active rejection have elevated donor-derived cell-free DNA.  19:1597-1598. 2019

Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients.  19:1218-1223. 2019

Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor—A multicenter analysis.  19:475-487. 2019

Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications.  19:123-131. 2019

Can you hear me now? Patient preferences for evaluating kidney transplant centers.  18:2624. 2018

Current opinions in organ allocation.  18:2625-2634. 2018

Organs from deceased donors with false-positive HIV screening tests: An unexpected benefit of the HOPE act.  18:2579-2586. 2018

Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation.  18:2483-2495. 2018

Response to “It is time to revise the kidney allocation system to restore the pediatric advantage”.  18:2367. 2018

Subclinical inflammation phenotypes and long-term outcomes after pediatric kidney transplantation.  18:2189-2199. 2018

Impact of the new kidney allocation system A2/A2B → B policy on access to transplantation among minority candidates.  18:1947-1953. 2018

Decreasing deceased donor transplant rates among children (≤6 years) under the new kidney allocation system.  18:1690-1698. 2018

Expanding clarity or confusion? Volatility of the 5-tier ratings assessing quality of transplant centers in the United States.  18:1494-1501. 2018

Response to: Regarding “HIV protease inhibitors and mortality following kidney transplantation”.  18:1571. 2018

Human polyomavirus-7–associated eruption successfully treated with acitretin.  18:1278-1284. 2018

Late graft failure after kidney transplantation as the consequence of late versus early events.  18:1158-1167. 2018

Assessing emergency department utilization in the era of population health.  18:777-778. 2018

Hospital readmissions following HLA-incompatible live donor kidney transplantation: A multi-center study.  18:650-658. 2018

Urologic malignancies in kidney transplantation.  18:13-22. 2018

Impact of Protease Inhibitor–Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant Recipients.  17:3114-3122. 2017

The Incremental Cost of Incompatible Living Donor Kidney Transplantation: A National Cohort Analysis.  17:3123-3130. 2017

B Cell Receptor Genes Associated With Tolerance Identify a Cohort of Immunosuppressed Patients With Improved Renal Allograft Graft Function.  17:2627-2639. 2017

Lessons Learned: Early Termination of a Randomized Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept.  17:2712-2719. 2017

PROviding Better ACcess To ORgans: A comprehensive overview of organ-access initiatives from the ASTS PROACTOR Task Force.  17:2546-2558. 2017

Urinary Markers of Fibrosis and Risk of Cardiovascular Events and Death in Kidney Transplant Recipients: The FAVORIT Trial.  17:2640-2649. 2017

Risk of End-Stage Renal Disease in HIV-Positive Potential Live Kidney Donors.  17:1823-1832. 2017

Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index.  17:1540-1548. 2017

The Influence of Race and Common Genetic Variations on Outcomes After Pediatric Heart Transplantation.  17:1525-1539. 2017

Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model.  17:1193-1203. 2017

Ureteral Obstruction and New Groin Pain in a Kidney Transplant Recipient.  17:1139-1141. 2017

Increased Mortality and Graft Loss With Kidney Retransplantation Among Human Immunodeficiency Virus (HIV)–Infected Recipients.  17:173-179. 2017

The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology.  17:28-41. 2017

Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study.  16:3468-3478. 2016

Splenic irradiation for the treatment of severe antibody-mediated rejection.  16:3041-3045. 2016

Anti–Blood Group Antibodies in Intravenous Immunoglobulin May Complicate Interpretation of Antibody Titers in ABO-Incompatible Transplantation.  16:2483-2486. 2016

Identification of Optimal Donor–Recipient Combinations Among Human Immunodeficiency Virus (HIV)–Positive Kidney Transplant Recipients.  16:2377-2383. 2016

Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected With Human Immunodeficiency Virus.  16:2368-2376. 2016

Proteomic Characterization Reveals That MMP-3 Correlates With Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation.  16:2342-2351. 2016

Anti-Leukocyte Function-Associated Antigen 1 Therapy in a Nonhuman Primate Renal Transplant Model of Costimulation Blockade-Resistant Rejection.  16:1456-1464. 2016

Economic Impacts of ABO-Incompatible Live Donor Kidney Transplantation: A National Study of Medicare-Insured Recipients.  16:1465-1473. 2016

Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk.  16:833-840. 2016

Presentation and outcomes of C4d-negative antibody-mediated rejection after kidney transplantation.  16:213-220. 2016

Where the Sun shines: Industry's payments to transplant surgeons.  16:292-300. 2016

First report on the OPTN national variance: Allocation of A2/A2B deceased donor kidneys to blood group B increases minority transplantation.  15:3134-3142. 2015

Hospital-onset Clostridium difficile infection among solid organ transplant recipients.  15:2970-2977. 2015

Longitudinal Studies of a B Cell-Derived Signature of Tolerance in Renal Transplant Recipients.  15:2908-2920. 2015

Center-Level Experience and Kidney Transplant Outcomes in HIV-Infected Recipients.  15:2096-2104. 2015

Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation.  15:2188-2196. 2015

Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure.  15:1615-1622. 2015

Solid organ transplantation from hepatitis B virus-positive donors: Consensus guidelines for recipient management.  15:1162-1172. 2015

A pilot trial targeting the icos-icos-l pathway in nonhuman primate kidney transplantation.  15:984-992. 2015

Loss of pediatric kidney grafts during the "high-risk age window": Insights from pediatric liver and simultaneous liver-kidney recipients.  15:445-452. 2015

Quantifying renal allograft loss following early antibody-mediated rejection.  15:489-498. 2015

The impact of proposed changes in liver allocation policy on cold ischemia times and organ transportation costs.  15:541-546. 2015

Frailty and mortality in kidney transplant recipients.  15:149-154. 2015

Emotional well-being of living kidney donors: Findings from the RELIVE study.  14:2535-2544. 2014

Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation.  14:459-465. 2014

Kidneys at higher risk of discard: Expanding the role of dual kidney transplantation.  14:404-415. 2014

Preoperative plasma club (Clara) cell secretory protein levels are associated with primary graft dysfunction after lung transplantation.  14:446-452. 2014

To transplant a kidney with the heart or not - That is the real question.  14:253-254. 2014

A randomized, double-blind, placebo-controlled, multicenter study of rabbit ATG in the prophylaxis of acute rejection in lung transplantation.  14:1191-1198. 2014

Epidemiology of invasive mold infections in lung transplant recipients.  14:1328-1333. 2014

Hemorrhagic shock one month following uncomplicated liver transplantation.  14:1461-1463. 2014

Quantifying the risk of incompatible kidney transplantation: A multicenter study.  14:1573-1580. 2014

Role of left ventricular assist devices in assessment of patients for combined heart-kidney transplantation.  14:1946-1947. 2014

Transmission of Balamuthia mandrillaris through solid organ transplantation: Utility of organ recipient serology to guide clinical management.  14:1417-1424. 2014

Inhibition of αvβ6 promotes acute renal allograft rejection in nonhuman primates.  13:3085-3093. 2013

What liver transplant outcomes can be expected in the uninsured who become insured via the affordable care act?.  13:1533-1540. 2013

Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older - United States, 2013.  13:1354-1363. 2013

Progressive multifocal leukoencephalopathy in a heart transplant recipient following rituximab therapy for antibody-mediated rejection.  13:1075-1079. 2013

The aggressive phenotype revisited: Utilization of higher-risk liver allografts.  13:936-942. 2013

Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion.  13:320-328. 2013

Demographic, metabolic, and blood pressure characteristics of living kidney donors spanning five decades.  13:390-398. 2013

A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients.  12:3061-3068. 2012

Erratum: A realistic proposal-incentives may increase donation - We need trials now! (American Journal of Transplantation (2012) 12 (1957-1958) DOI:10.1111/j.1600-6143.2012.04117.x).  12:2261. 2012

Report of a consensus conference on transplant program quality and surveillance.  12:1988-1996. 2012

The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival.  12:1924-1928. 2012

Organ donation and moyamoya disease.  12:1353-1355. 2012

A response to child-to-parent donationa-consideration of age and ethnicity.  12:503. 2012

Counseling patients for kidney transplantation: Awkward conversations?.  12:273-274. 2012

A realistic proposal - Incentives may increase donation - We need trials now!.  12:1957-1958. 2012

The PROMISE study: A phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de Novo kidney transplantation.  11:2675-2684. 2011

Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis.  11:2517-2522. 2011

The impact of pretransplant mechanical ventilation on short- and long-term survival after lung transplantation.  11:2197-2204. 2011

Ethnic and gender related differences in the risk of end-stage renal disease after living kidney donation.  11:1650-1655. 2011

Elevated plasma Clara cell secretory protein concentration is associated with high-grade primary graft dysfunction.  11:561-567. 2011

Living donor nephrectomy: Understanding long-term risk in minority populations.  10:2574-2576. 2010

Association of race and socioeconomic position with outcomes in pediatric heart transplant recipients.  10:2116-2123. 2010

Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access.  10:2154-2160. 2010

Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure.  10:2066-2073. 2010

Access and outcomes among minority transplant patients, 1999-2008, with a focus on determinants of kidney graft survival: Special feature.  10:1090-1107. 2010

Proinflammatory events and HLA antibodies..  10:956. 2010

Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: Preliminary data from the DeKAF study.  10:315-323. 2010

Pathological and clinical characterization of the 'Troubled transplant': Data from the DeKAF study.  10:324-330. 2010

Candida in solid organ transplant recipients.  9. 2009

Impact of medicare coverage on disparities in access to simultaneous pancreas and kidney transplantation.  9:2785-2791. 2009

Long-term management of the liver transplant patient: Recommendations for the primary care doctor: Special feature.  9:1988-2003. 2009

Use of cardioprotective medications in kidney transplant recipients.  9:1811-1815. 2009

Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: The opticept trial.  9:1607-1619. 2009

Secondary listing for deceased-donor kidney transplantation does not increase likelihood of engraftment at a large transplant center: Brief communication.  9:1671-1673. 2009

Transplant tourism and unregulated black-market trafficking of organs.  9:1484. 2009

Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate.  9:1243-1248. 2009

Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation.  9:389-396. 2009

Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody.  9:2136-2139. 2009

The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.  9:231-235. 2009

Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: Preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics.  8:1711-1718. 2008

Effect modification in liver allografts with prolonged cold ischemic time.  8:658-666. 2008

Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation.  7:2573-2578. 2007

Heart retransplantation.  7:2075-2081. 2007

Outcomes of kidneys from donors after cardiac death: Implications for allocation and preservation.  7:1797-1807. 2007

Adeno-associated viral vector-mediated interleukin-10 prolongs allograft survival in a rat kidney transplantation model.  7:1112-1120. 2007

Must all living donor compensation be viewed as valuable consideration? [2].  7:1309-1310. 2007

The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection.  7:842-846. 2007

Cold ischemia time and allograft outcomes in live donor renal transplantation: Is live donor organ transport feasible?.  7:99-107. 2007

Limiting financial disincentives in live organ donation: A rational solution to the kidney shortage.  6:2548-2555. 2006

The conspicuous costs of more of the same.  6:1503-1504. 2006

Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: Reanalysis of the multicenter trial.  6:993-997. 2006

Invasive fungal infections in low-risk liver transplant recipients: A multi-center prospective observational study.  6:386-391. 2006

Acute Graft versus host disease after liver transplantation: Patterns of lymphocyte chimerism.  5:2968-2973. 2005

Understanding the influence of ethnicity on renal allograft survival.  5:2603-2604. 2005

Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts.  5:2248-2252. 2005

Kidneys from deceased donors: Maximizing the value of a scarce resource.  5:1725-1730. 2005

Long-term deterioration of kidney allograft function.  5:1405-1414. 2005

Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: The Israel Penn International Transplant Tumor Registry experience.  5:775-780. 2005

Thoracic organ transplantation in the United States, 1994-2003..  5:934-949. 2005

African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression.  5:356-365. 2005

Thoracic organ transplantation in the United States, 1994-2003.  5:934-949. 2005

Evidence for cooperativity in the rejection of cardiac grafts mediated by CD4⁺ TCR Tg T cells specific for a defined allopeptide.  4:1762-1768. 2004

Calcium oxalate deposition in renal allografts: Morphologic spectrum and clinical implications.  4:1338-1344. 2004

Whither Living Donors?.  4:2-3. 2004

Equivalent Pharmacokinetics of Mycophenolate Mofetil in African-American and Caucasian Male and Female Stable Renal Allograft Recipients.  3:1581-1586. 2003

Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: Effective CMV prevention following daclizumab induction.  3:492-496. 2003

Relative perioperative bradycardia does not lead to adverse outcomes after cardiac transplantation.  3:484-491. 2003

Determinants of cardiovascular mortality after renal transplantation: A role for cytomegalovirus?.  3:79-81. 2003

Diabetes mellitus after kidney transplantation.  3:512-513. 2003

Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C.  3:626-630. 2003

The report of a national conference on the wait list for kidney transplantation.  3:775-785. 2003

Hand-assisted laparoscopic living-donor nephrectomy as an alternative to traditional laparoscopic living-donor nephrectomy.  2:983-988. 2002

Use of preserved vascular homografts in liver transplantation: Hepatic artery aneurysms and other complications.  2:471-475. 2002

The general public's concerns about clinical risk in live kidney donation.  2:186-193. 2002

Addressing minority issues in renal transplantation: Is more equitable access an achievable goal?.  2:1-3. 2002